Abstract: The present invention relates to amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder.

Abstract: The present invention relates to oxygenated amino or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.

Abstract: The present invention relates to hydroxy-substituted amino and ammonium derivatives, in particular the compounds of formula (1) or (2), and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.

Abstract: The present invention relates to a method for the treatment and/or amelioration of urticaria, the method comprising the administration of a pharmaceutically active dose of a compound of formula I to a subject in need of such a treatment and/or amelioration.

Abstract: The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization and/or activation. Preferred in this context are Edelfosine, Miltefosine and Perifosine. In a particularly preferred embodiment, the present invention relates to the use of Miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma, atopic dermatitis and mastocytosis.

Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen, wherein said antigen is NGF antigen. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of pain. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses.

Abstract: The present invention relates to a method for the treatment and/or amelioration of atopic dermatitis, the method including the administration of a pharmaceutically active dose of a compound selected from miltefosine, edelfosine, perifosine and ilmofosine to a subject in need of such a treatment and/or amelioration.

Abstract: The present invention relates to the use of specific carbazole derivatives in the preparation of medicaments for the treatment, prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.

Abstract: The present invention relates to specific sphingolipids/sphingolipid derivatives as pharmaceutical compositions as well as their use in the preparation of medicaments for the treatment, prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.

Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides a composition comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of allergic diseases with an eosinophilic component and as a pharmaccine to prevent or cure allergic diseases with an eosinophilic component and to efficiently induce immune responses, in particular antibody responses.

Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus like particle (VLP) and at least one GnRH peptide or fragment or variant thereof linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of GnRH-related diseases and conditions and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

Abstract: The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization. Preferred in this context are edelfosine and miltefosine. In a particularly preferred embodiment, the present invention relates to the use of miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma.

Abstract: The present invention relates to a compound comprising a tripartite structure in the format C-B-A or C?-B?-A? wherein moiety A and moiety A? is a raftophile, moiety B and moiety B? is a linker, moiety C and moiety C? is a pharmacophore; and wherein moiety B and B? is a linker which has a backbone of at least 8 carbon atoms and wherein one or more of said carbon atoms may be replaced by nitrogen, oxygen or sulfur. Furthermore, specific medical and pharmaceutical uses of the compounds of the invention are disclosed.

Abstract: The present invention is in the fields of medicine, immunology, virology and molecular biology. The present invention provides a composition comprising a modified virus-like (VLP) particle derived from RNA bacteriophage AP205. The invention also provides a process for producing the aforementioned VLP. The modified VLP disclosed in the present invention is useful in the production of compositions for inducing immune responses for the prevention or treatment of diseases, disorders including infectious diseases, allergies, cancers and drug addiction. Moreover, the modified VLP disclosed in the present invention is, in particular, useful to efficiently induce self-specific immune responses, in particular antibody responses.

Abstract: The present invention relates to the use of specific steroid derivatives in the preparation of medicaments for the treatment or prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.

Abstract: A blind rivet formed with a tubular shell, and a mandrel extending through the shell. The shell has an outwardly extending flange at one end forming a rivet head, and having a first set of radial indentations arranged around the periphery of the shell at a first distance from the rivet head, and a second set of radial indentations arranged around the periphery of the shell at a second distance from the rivet head. Each of the radial indentations are formed by crimping them in the rivet shell after the shell has been positioned around the mandrel with the end of the shell remote from the rivet head defining the blind end of the rivet shell. Lastly, the mandrel having a head formed at one end to abut against the blind end of the shell, and the stem extending from the head having a point of weakness part way along the length thereof disposed within the shell.

Abstract: The present invention relates to specific sphingolipids/sphingolipid derivatives as pharmaceutical compositions as well as their use in the preparation of medicaments for the treatment, prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.

Abstract: A blind rivet formed with a tubular shell, and a mandrel extending through the shell. The shell has an outwardly extending flange at one end forming a rivet head, and having a first set of radial indentations arranged around the periphery of the shell at a first distance from the rivet head, and a second set of radial indentations arranged around the periphery of the shell at a second distance from the rivet head. Each of the radial indentations are formed by crimping them in the rivet shell after the shell has been positioned around the mandrel with the end of the shell remote from the rivet head defining the blind end of the rivet shell. Lastly, the mandrel having a head formed at one end to abut against the blind end of the shell, and the stem extending from the head having a point of weakness part way along the length thereof disposed within the shell.

Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides a composition comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of allergic diseases with an eosinophilic component and as a pharmaccine to prevent or cure allergic diseases with an eosinophilic component and to efficiently induce immune responses, in particular antibody responses.

Abstract: A cart assembly comprises an undercarriage supporting a cart frame, the undercarriage having one end and a connecting portion extending from cart frame and/or the undercarriage for connecting the cart assembly with an adjacent article, the cart frame including a handle portion disposed at an elevation for manipulation by a human operator in an upright standing position to steer or otherwise control the cart assembly, and an actuating member mounted on the handle portion for actuating the connecting portion between a first connecting position and a second disconnecting position.